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only to optometrists, ophthalmologists,
and opticians-who often mark up the
lens prices significantly-and not to alternative channels of distribution such as
pharmacies, mail-order firms, and similar
entities which may offer discounted prices
on the lenses. The action further claims
that the named optometrists and the Society tried to persuade lens manufacturers
not to distribute soft lenses to alternative
chains of distribution, and that the Society
threatened not to prescribe the lenses of
any manufacturer which sold its product
to pharmacies or mail-order channels of
distribution. At this writing, the matter is
not expected to be heard until at least late
1996 or early 1997.

* RECENT MEETINGS
At its December 1-2 meeting, in response to questions regarding the amount
of time necessary to complete the rulemaking process, the Board reviewed the procedural requirements which must be met
in order to adopt, amend, or repeal a regulation; staff will also prepare and distribute a flowchart explaining the rulemaking
process as set forth in the Administrative
Procedure Act.
Also at its December meeting, the Board
reelected John Anthony, OD, to serve as
President; Robert Dager, OD, to serve as
Vice-President; and Mona Tawatao to serve
as Secretary.
* FUTURE MEETINGS
March 15-16 in Anaheim.
May 13-14 in San Jose.
August 22-23 in Sacramento.
November 18-19 in San Diego.

BOARD OF PHARMACY
Executive Officer: Patricia Harris
(916) 445-5014

p

ursuant to Business and Professions
Code section 4000 et seq., the Board
of Pharmacy grants licenses and permits
to pharmacists, pharmacies, drug manufacturers, wholesalers, medical device retailers, and sellers of hypodermic needles.
It regulates all sales of dangerous drugs,
controlled substances, and poisons. The
Board is authorized to adopt regulations,
which are codified in Division 17, Title
16 of the California Code of Regulations
(CCR). To enforce its regulations, the Board
employs full-time inspectors who investigate complaints received by the Board.
Investigations may be conducted openly
or covertly as the situation demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized by
114

law to suspend or revoke licenses or permits for a variety of reasons, including
professional misconduct and any acts substantially related to the practice of pharmacy.
The Board consists of ten members,
three of whom are nonlicensees. The remaining members are pharmacists, five of
whom must be active practitioners. All are
appointed for four-year terms.
In May 1995, Board member Kent
Wilcox resigned, but will continue to
serve until Governor Wilson appoints his
replacement.

U

MAJOR PROJECTS

Distribution of Drug Samples. On
May 24, the Board held an informational
hearing on the distribution of drug samples in California. Under the current system of distribution, sales representatives
of drug manufacturers supply physicians
with drug samples to be dispensed directly
to patients. The Board held the hearing to
receive comments on whether this system
provides the best approach to a patient's
drug therapy, and to explore alternative
approaches to the current system of drug
sample distribution.
An issue paper which accompanied the
Board's hearing notice identified the positive outcomes of drug sample therapy;
specifically, the Board stated that drug
sample distribution allows patients to begin
drug therapy immediately, reduces patient
costs, and allows physicians to readily test
a patient's reaction to the drug. However,
the Board expressed concerns that drug
samples are not monitored and accounted for
during their handling, transportation, and
distribution to physicians. Other unresolved
issues arising out of the distribution and
dispensing of drug samples include the fact
that no record of use or monitoring of the
drug therapy can be maintained by a pharmacist; without record of use, the pharmacist
is unable to evaluate a drug's interaction
with the patient's entire medication regimen
to prevent adverse reactions; the patient will
not receive counseling on the use of the drug
from a pharmacist; the potential for diversion of drug samples for unintended use by
patients; the unauthorized sale of samples by
pharmacies; the fact that unlicensed sales
representatives of drug manufacturers have
access to drugs with no state oversight of
storage conditions or means of accounting
for quantities dispensed; and the lack of a
means to track a drug sample if it is recalled.
The Board is considering an alternative to the current system of sample distribution through the use of a voucher/coupon method of distribution. Under this
proposal, a physician could issue a voucher
or coupon to a patient, allowing the patient

to receive a free sample quantity of a drug
from a pharmacy; the free amount that is
dispensed would then be billed to the manufacturer.
During the informational hearing, the
Board considered comments from manufacturers, practitioners, and representatives of professional associations in support of and in opposition to modifying the
existing system of drug sample distribution. In support of the status quo, Dr. Ben
Shwachman of the California Medical Association (CMA) stated that the Board has
not identified and proven that a problem
exists under the current system. Furthermore, CMA contends that current law adequately regulates manufacturers and physicians in the distribution and dispensing
of drug samples. Others in favor of the
current system noted that the alternative
voucher system would only add more
recordkeeping requirements and increase
costs; issues of distribution accountability
and control should not impair the availability of samples to the medically indigent; pharmacists' inability to update patient drug records is not a realistic justification to discredit the dispensing of drug
samples by physicians in light of the numerous prescriptions filled by out-of-state
pharmacies; physicians maintain documentation of sample drugs dispensed in
the patient's records along with results of
the medical examination for which the
drug therapy was recommended; and diversion is not a serious health concern
since samples do not include Schedule II
drugs.
In opposition to the current method of
dispensing drug samples, Robert Marshall
of the California Pharmacists Association
(CPhA) expressed support for the alternative voucher method of dispensing samples through a pharmacy. CPhA contends
that the proposed method would allow
entry of relevant data in the patient profile,
eliminate the waste of different packaging
used on sample sizes, afford patients adequate labeling not found on samples, and
provide the opportunity for oral consultation with a pharmacist. Those also opposed to the existing system of drug sample distribution emphasized that patients
to whom samples are dispensed are not
receiving drugs judged on their pharmacological merits but as a result of marketing
strategies. Other advocates of the proposed voucher system contend that the
alternative method of sample distribution
would better protect the public through the
services offered by a pharmacist and the
safeguards of drug accountability.
Following public comments, the Board
clarified that physicians are held to the
same standards required of pharmacists
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with respect to the labeling of drug medications dispensed to a patient, including
samples. Furthermore, medical offices are
subject to the same recordkeeping and storage requirements as are pharmacies.
At its July 26 meeting, the Board continued to review comments presented at the
informational hearing in May, as well as
written comments submitted thereafter. The
Board discussed its concern that a non-licensed sales representative of a drug manufacturer may handle and transport legend
items (i.e., those drugs not available over the
counter). Deputy Attorney General William
Marcus informed the Board that sales representatives are authorized under federal
and/or state law to handle and transport
drugs as agents of businesses appropriately
licensed or registered by the Department
of Health Services or by the Board; the
storage of drugs in a sales representative's
car is permitted as an extension of a manufacturer's licensed premises.
Following discussion, the Board decided by a vote of 7-1 to table the issue
and appoint a study group to conduct further research and review relevant documents on the current system of drug sample distribution and viable alternatives. In
the interim, the Board will send notices to
the Medical Board of California, the Osteopathic Medical Board of California, the
Board of Dental Examiners, the Board of
Podiatric Medicine, and the Veterinary
Medical Board reiterating the legal requirements regarding sample drug labeling, distribution, and handling by their
prescribers.
Pharmacy Technician Program:
"Tech Check Tech" (TCT) Proposal.
During the past twenty years, pharmacy
technicians have worked in hospitals
under the supervision of registered pharmacists. It was not until 1991 that the
legislature enacted a bill establishing a
pharmacy technician certification program for all practice settings. AB 1244
(Chapter 841, Statutes of 1991) authorized the use of pharmacy technicians to
perform the repetitive, non-discretionary
tasks of filling prescriptions under the direct supervision of a licensed pharmacist.
[11:4 CRLR 105-06]
A pharmacy technician's tasks include
measuring out quantities of drugs for dispensing as prescribed and entering prescription information into patient records.
While pharmacists are relieved from performing these tasks, they are required to
check the work performed by their pharmacy technicians. The delegation of these
tasks was intended to give a pharmacist
time to provide patients with oral consultation on the use of the drugs dispensed in
compliance with existing law. [14:2&3

CRLR 94] However, AB 1244 was only
intended to regulate pharmacy technician
programs in community pharmacies, leaving intact the longstanding practices of
hospital pharmacies; hence, inpatient hospital pharmacy technicians were exempt
from such requirements as registration with
the Board. Consequently, a dual system of
regulation has resulted, with less stringent
statutory standards required of hospital
pharmacy technicians than for technicians
in other practice settings.
In July 1993, the Board appointed a
Hospital Committee to evaluate the technician program in hospital pharmacies and
focus on the possibility of authorizing
pharmacy technicians in the hospital setting to check the work of other pharmacy
technicians. The Committee concluded
that a pharmacist's expertise is used most
effectively in reviewing drug orders and
in attending to patient needs, but not in the
task of checking technicians. The Hospital
Committee submitted to the Board an initial draft of proposed new section 1793.8,
Title 16 of the CCR, which would permit
pharmacy technicians in general acute
care hospitals who meet certain requirements to check the work of other pharmacy technicians in connection with the
filling of floor and ward stock and unit
dose cassettes for patients whose orders
have previously been reviewed by a pharmacist.
On May 24, the Board held an informational hearing to evaluate the pharmacy
technician program. The Board solicited
comments on the program's effectiveness,
recommended changes for improvement,
and comments on the draft version of section 1793.8. The Board received comments in support of and opposition to the
proposal to implement a program allowing hospital pharmacy technicians to
check the work of other technicians.
Supporters of draft section 1793.8,
such as California Society of Health-System Pharmacists (CSHP) and Kaiser Permanente (Kaiser), urged the adoption of
the section to establish requirements for
TCT programs in acute care hospitals.
Representing CSHP, Teresa Miller explained that technicians have been checking technicians in California hospitals for
years; although the Board's official position is that such practice contravenes current regulations, Board inspectors have
ineffectively dealt with such ongoing violations in hospital pharmacies. Albert
Carver of Kaiser suggested that section
1793.8 is long overdue as Board regulations have not kept pace with developments in the profession over the years.
In agreement with CSHP and Kaiser,
the University of California School of Phar-
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macy reported that the changing role of
hospital pharmacists requires their availability to participate in patient pharmaceutical care as part of a clinical team of
doctors, nurses, and pharmacists. The California Association of Hospital and Health
Systems and the Golden Gate Society of
Health-System Pharmacists joined in support of expanding the technician program;
both suggested that the less stringent statutory requirements for hospital pharmacy
technicians are due to the quality assurance process which already exists in hospitals in the form of hospital rules, regulations, and accreditation standards.
However, those in opposition to the
TCT proposal asserted their unified position that patient harm will result from allowing unsupervised pharmacy technicians to check the work of other pharmacy
technicians. Phillip Grauss, President of
the Marin County Pharmaceutical Association and appearing on behalf of twenty
local California pharmacy associations, emphasized that part of the "pharmaceutical
care" expected of a pharmacist is checking
and correcting the potentially lethal mistakes made by pharmacy technicians; while
acknowledging that everyone-including
pharmacists-makes mistakes, Grauss recognized that a pharmacist is more likely to
perform his/her duties conscientiously to
protect his/her license and to uphold a
professional duty to provide quality patient care. In contrast, Grauss contended
that pharmacy technicians do their tasks
mechanically; he opined that their tendency to glance over filled prescriptions
without scrutinizing for accuracy makes
them inappropriate to be responsible for
the final check in the process of dispensing drugs. Robert Marshall of CPhA challenged the results of research projects presented at the hearing which indicated that
pharmacy technicians are at least as proficient as pharmacists at the task of checking completed prescription orders in the
inpatient environment; CPhA further offered to conduct a survey of all California
pharmacists to determine their experience
with the use of pharmacy technicians.
Marshall also spoke on behalf of six
professional organizations in presenting a
joint Statement on Pharmacy Technicians
in which several concerns and suggestions
for improving the program were discussed. The Joint Statement opposed allowing pharmacy technicians to check the
prescription preparation of other technicians under any circumstances, regardless
of the practice setting. The Joint Statement
further addressed pharmacist liability;
while these six organizations agreed that
the supervising pharmacist must assume
legal responsibility for all pharmacy ser-
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vices performed by a technician, they reasoned that a supervising pharmacist cannot and should not be liable for the work
of a technician whom the pharmacist does
not personally inspect. The Joint Statement also questioned the exemption of
inpatient hospital pharmacy technicians
from the requirement of Board registration; in effect, those pharmacy technicians
are not subject to a criminal background
check completed during the process of
registration, defeating a safety mechanism
against potential drug diversion.
Despite their differences on the TCT
issue, both proponents and opponents of
the TCT proposal agreed that the Board
must adopt additional regulations to improve the pharmacy technician program.
There appeared to be a general consensus
that registration and certification should
be required of all pharmacy technicians,
including technicians at inpatient facility
pharmacies who are currently exempt; further, many opined that continuing education should be required of all technicians
as a prerequisite to registration renewal.
In its May 24 discussion, the Board
grappled with the currently illegal practice
of techs checking techs in California's hospitals. The Board noted that an illegal
procedure which becomes a standard of
practice is still illegal; however, a practice
so pervasive in California's hospitals makes
enforcement of current regulations problematic. The Board noted that an alternative to enforcement is the revision of current laws and regulations to reflect professional practices that get ahead of the law.
At its July 26 meeting, the Board resumed its discussion of the TCT issue.
After reviewing the comments received at
the May 24 informational hearing and the
numerous comments submitted thereafter,
the Board also considered the fact that
similar TCT programs are permitted in the
states of Washington and Minnesota. The
Board decided by a vote of 6-1, with one
abstention, to move forward with a regulation hearing to take action on the adoption of proposed section 1793.8.
On September 1, the Board published
notice of its intent to adopt section 1793.8
and amend section 1793.7. Following an
October 25 public hearing, the Board
voted 6-3 to reject the proposed changes;
however, the Board further decided to
form and refer the issue to a pharmacy
technician committee to conduct a general
review of the technician program and explore the issue of registration of hospital
pharmacy technicians.
Automation of the Triplicate Program. On July 18, the Board's Oversight
Committee on the Automation of the Triplicate Program (Oversight Committee) ap116
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proved the final version of the Feasibility
Study Report (FSR) prepared by the Hawkins Data Center; the goal of the study was
to research and develop an automated information system to process Schedule II
drugs, which are currently processed manually through a paper-based triplicate system. This triplicate system monitoring
program is administered by the Bureau of
Narcotics Enforcement (BNE) under the
California Department of Justice (DOJ).
The FSR proposed the creation of an electronic system called the Controlled Substance Utilization Review and Evaluation
System (CURES), which would electronically monitor and track controlled substance prescriptions dispensed statewide.
[15:2&3 CRLR 89; 15:1 CRLR 86]
Also at its July 18 meeting, the Oversight Committee discussed seeking funding in order to implement the CURES
project; according to the CURES Funding
Subcommittee, about $500,000 is needed
to implement CURES. According to the
FSR timeline, if funding is granted in
July 1996, the earliest implementation of
CURES would be January 1998. To avoid
further postponement in implementing
CURES, the Oversight Committee is seeking federal and state funding while encouraging agencies responsible for regulating healing arts professions to contact
Attorney General Dan Lungren and ask
him to find funding for the CURES program during this fiscal year.
Also on July 18, the Oversight Committee discussed the parallel issue of seeking legislation authorizing the Board to
implement the electronic tracking system
for Schedule II drugs. While the authority
to maintain a controlled substance tracking system currently rests with BNE, the
Board is concerned that if funding is not
granted, the automation project will not go
forth. Should efforts to seek funding for
the program in fiscal year 1996-97 fail,
the Committee intends to seek DOJ's support of legislation in 1996 to transfer the
controlled substance monitoring program
to the Board.
At its July meeting, the Board decided
by a vote of 7-1 to seek legislation to place
with the Board the monitoring program
for controlled substances, including any
paper-based or electronic monitoring system, but only in the event BNE's appeal
for federal and state funding is denied. At
its October 26 meeting, the Board considered for future action the possibility of
becoming a co-applicant with the Department of Justice in seeking federal funding
of the CURES project.
"Third Class" of Drugs. Under current law as established by the federal Food
and Drug Administration (FDA), two

classes of drugs exist: prescription drugs
and nonprescription or over-the-counter
(OTC) drugs. While prescription drugs are
dispensed only under the order of a licensed
prescriber and used under the prescriber's
direct supervision, OTC drugs may be purchased without a prescription and are to be
used according to the required label directions and warnings. Nonprescription drugs
must satisfy the FDA's safety standards and
labeling requirements to become available
over the counter.
As more drugs transition from prescription-only status to OTC availability, the
Board is concerned about the effects on
patient care. When prescription drugs become available for public sale and use, the
issue of concern is the patient's appropriate use of the drug without the oversight
of a health care professional. At its July 26
meeting, the Board discussed a proposal
to seek the establishment of a third class
of drugs which could only be sold by a
health professional authorized by law to
prescribe or dispense such drugs.
In 1992, CPhA sponsored AJR 63,
which stated California's support for a
proposal authorizing the FDA to establish
a transitional nonprescription category of
drugs available only through a licensed
pharmacist. [12:4 CRLR 117] However, a
"transitional" class of drugs is distinct
from the Board's proposed "third class" of
drugs. The "third class" concept represents a permanent and fixed new category
of drugs, neither prescription nor OTC,
and available only through a pharmacist;
a "transitional" class is intended to facilitate a drug's transition to OTC status for
general sales, and therefore would only
temporarily restrict access by requiring
purchase through a pharmacist for a limited time during which drug use consultation could be given.
Although support for an intermediate
class of drugs exists among pharmacists'
professional organizations, a recent report
from the U.S. General Accounting Office
(GAO) questioned the benefits of creating
such a class. In August 1995, GAO issued
a report entitled Nonprescription Drugs:
Value of a Pharmacist-Controlled Class
Has Yet To Be Demonstrated, which summarizes a study of the drug distribution
system of ten countries and the state of
Florida, all of which have some form of an
intermediate class of drugs. GAO's report
concludes that there is a lack of evidence
at this time to support a fundamental
change to the existing two-class drug distribution system. The report adds that the
benefits of an intermediate class, fixed or
transitional, are unclear and no evidence
exists to show the overall superiority or
inferiority of a system that restricts the
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sale of at least some nonprescription drugs
to pharmacies.
On October 25, the Board held an informational hearing on the establishment
of a third class of drugs. The Board solicited comments and suggestions from pharmaceutical manufacturers of over-thecounter and prescription drugs, consumer
groups, health care professionals, and
pharmacy organizations. At the hearing,
the Nonprescription Drug Manufacturers
Association (NDMA) opposed the creation of a third class of drugs in California.
NDMA contended that FDA's detailed
procedure for approving a drug's switch to
nonprescription status assures that OTC
drugs are safe and effective for use, and
that the procedure requires manufacturers
to research each drug's safety and efficacy
and follow up on adverse events pre- and
post-marketing. NDMA further informed
the Board that drug manufacturers have
developed consumer education programs
to promote the safe use of OTC drugs;
NDMA itself has undertaken a joint promotion with Reader's Digest to inform the
public about reading labels, the proper use
of medication, and the dangers of mixing
drugs. Finally, NDMA contended that although expanding the role of pharmacists
in a new intermediate drug class to improve drug use is justified, GAO's report
suggests that the benefits are uncertain.
The California Retailers Association (CRA)
also opposed the creation of a third class
of drugs. CRA argued that in matters of
self-health care, the current system effectively empowers consumers with a widening selection of medicines for self-care
deemed safe and effective by FDA, keeps
health care costs low due to competitive
prices, and makes nonprescription medicines more widely accessible at convenient
times and varied locations. CRA contended
that a new intermediate class of drugs
would increase health care costs and diminish access, resulting in a disproportionate impact on the traditionally underserved
populations in urban and rural areas of the
state.
The National Association of Boards of
Pharmacy (NABP) has had a longstanding
policy in support of a nonprescription, third
class of drugs. According to NABP, the
limitation on who can dispense the drug
would further the goal of providing patients with the opportunity to consult with
a health care professional on the proper
use of drug medication. NABP has expressed a general concern that more consumers will start to diagnose their own
illnesses and misuse a drug. In addition,
several pharmacists' professional organizations and individual community pharmacists testified at the Board's informa-

tional hearing in support of creating an
intermediate class of drugs.
The American Pharmaceutical Association (APhA) testified that APhA has publicly supported the availability of medication without prescription for self-care since
1964, while urging development of adequate safeguards to assure safe and effective drug use. APhA believes these goals
can be achieved through the development
of a transitional class of drugs. APhA expressed concern that while an OTC drug
is safe for use if a patient follows the directions and heeds the warning, consumers
have and will continue to imprudently mix
and match medications. APhA believes
that a transitional class of drugs would
benefit consumers through education by
requiring consumers to receive advice from
a professional health care provider on the
proper use of a medication before it later
becomes an OTC drug.
CPhA similarly expressed its longstanding policy of supporting a transitional class
of drugs. CPhA suggested that the Board
consider creating a transitional class of drugs
rather than a fixed, third class of drugs in the
effort to employ a pharmacist as an active
safeguard against improper drug use. CPhA
opined that it is not the role of the pharmacist
to make a drug safer; rather, it is the role of
the pharmacist to make the use of the drug
more appropriate.
The California Society of Hospital
Pharmacists (CSHP) also supported further pursuit of a transitional class of drugs
as an opportunity to facilitate the transfer
of a drug from prescription to OTC status.
CSHP suggested that the Board consider
model programs where a third class of
drugs exist, as in Florida. CSHP further
expressed its support of the Board's efforts
to promote the pharmacist's involvement
in the provision of pharmaceutical care.
While the supporters above advocated
creation of an intermediate class of drugs
to serve as a transitional phase, some parties favored a permanent third class of
drugs. The Pharmacist Planning Services,
Inc. (PPSI) supports the creation of a third
class of drugs where pharmacist consultation is mandatory and transition to OTC
status is not automatic, but subject to evaluation of reports of the drug's adverse
reactions, side effects, and other problems. PPSI suggested allowing a two-year
trial period to lapse before making the
decision to advance a drug to OTC status,
return it to prescription-only, or keep the
drug in the third class. PPSI also claims
that OTC drug manufacturers have done
little to improve labels on OTC drugs,
despite PPSI's petition to the FDA and
CPhA's introduction of a legislative resolution to increase print size.
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At the conclusion of the informational
hearing, Board President Marilyn Standifer Shreve announced that all comments
will be considered for discussion and action at the Board's January 1996 meeting.
Automated Medication Dispensing
System. On October 25, the Board received a report from Patient Care Pharmacy (PCP) on the results of a trial study
on the use of a Pyxis medstation in a
long-term care facility. In May 1994, the
Board and the Department of Health Services jointly approved a pilot project proposed by PCP to study the use of a Pyxis
medstation, an automated medication dispensing system, in a long-term facility; the
project was aimed at evaluating whether
the use of an automated medstation could
improve the process by which a subacute
health care facility receives prescription
medication from an off-premise pharmacy.
[14:4 CRL? 931
PCP's president, Dr. Eileen Goodis,
explained that as a result of changes in
health care, patient care is increasingly
shifted from acute care hospitals to subacute care settings such as nursing homes,
home care, and hospice care. Unlike hospitals, long-term care facilities do not have
in-house pharmacies, but must rely instead on deliveries from a pharmacy offpremise where prescriptions are filled. In
an emergency, a long-term care facility
has access to medication from an emergency drug kit to be used to administer the
first-time dose of a prescribed drug. Existing regulations allow the kits to be stocked
with 24 different single-dose oral medications. According to PCP regional vicepresident Ken Chen, use of the emergency
kit is virtually unmonitored, allowing drugs
to be removed without any pharmacist
screening. The lack of security measures
to monitor the storage and dispensing of
drugs kept in an emergency drug kit is
corrected in the automated medstation system.
The Pyxis automatic medstation, with
a design similar to that of automated teller
machines, has a 150-200 unit dose medication capacity. The medstation, which
would only be available at the nursing
station, is designed to interface directly
with the pharmacy patient profile system
to update the patient profile and document
each transaction which occurs at the medstation. The Pyxis machines currently used in
other states are refilled once a week with
the same drugs dispensed during the previous week, as determined by the dispensing pharmacy which electronically generates a report of dispensed drugs. While a
pharmacist placed the refilled drugs in the
medstation during this pilot study, in other
states the machine is restocked by a nurse.
11
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Once restocking is completed, the information is sent back online to the pharmacy
to be checked to ensure accountability.
PCP's pilot study demonstrated that
the accuracy and accessibility of the first
dose of medication was improved through
the use of an onsite automatic medication
dispensing machine. The study was conducted at a long-term care facility, on a
thirty-bed subacute care nursing station. A
control group of 54 random new orders,
accounting for approximately 33% of total
new orders, was studied during a threemonth period prior to implementation of
the automated system. This control group
was used to illustrate the three stages of
the current distribution system: the care
facility nurse telephones or faxes the prescription order to the pharmacy; the pharmacist screens the order by accessing the
pharmacy database to review the patient's
profile; and once approved and filled by
the pharmacist, the prescription is delivered to the nursing station at the care facility to be administered to the patient. An
obvious disadvantage of the current system is the delay in receiving the medication which the patient may need immediately; depending on the location of
the nursing facility and traffic, delivery
may take several hours.
A considerable time saving occurred in
administering medications to patients with
the automated system. At the same thirtybed subacute long-term care nursing station, a different 54 random new orders
(accounting for approximately 33% of total
new orders) were studied during a second
three-month period of implementing the
automated system. While the initial two
steps of sending the order to the pharmacy
and allowing the pharmacist the opportunity to screen the order are identical to that
in the current system described above, the
last step of delivering the medication is
more efficiently accomplished. Under the
automated system, when the pharmacist
has reviewed the order, he/she then electronically transmits the approval for the
medication dose to the online medstation
located at the facility which placed the
order. This allows a nurse at the care facility to access the medstation only to remove the first dose of a specific type of
medication as dispensed by the pharmacist's
electronic approval. Because travel time is
eliminated, patients at a care facility which
is remote from a pharmacy can receive
their medication as soon as their prescription is approved and transmitted by the
pharmacist.
Another issue the Board discussed is
legal limitations on the continued use of
the Pyxis automated medstation in any
expanded pilot project. Under current law,
18
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no provision allows for the storage of dangerous drugs, including controlled substances, in facilities other than pharmacies, hospital pharmacies, community, free
or surgical clinics, manufacture or wholesaler premises, and physician offices. Further, Deputy Attorney General Bill Marcus explained that under existing law, the
authority to dispense Schedule II controlled
substance medications, in other than an
emergency, is limited; no Schedule II drugs
may be dispensed without a triplicate form
prescription or for an amount that would
exceed a 72-hour supply. While the pilot
study limited the administration of a controlled substance medication to the first
dose only, which is clearly within the allowable dosage supply limit, the Board
will need to address the issue of administering Schedule II drugs, if any, to comply
with dispensing requirements established
by the Bureau of Narcotic Enforcement.
Following discussion, the Board decided by a vote of 7-1, with one abstention, to support further study of this program in conjunction with a school of pharmacy; the Board also voted to work with
Patient Care Pharmacy and other organizations to cosponsor legislation to provide
for the authorized use of the automated
dispensing machines in long-term care facilities.
Minimum Standards for Wholesalers. On November 11, the Board published
notice of its intent to amend section 1780,
Title 16 of the CCR, which describes the
minimum standards for all wholesale establishments for which the Board issues
permits. The Board's proposed changes
would remove from the section an existing
requirement that floor plans and elevations of the storage area of a pharmacy
wholesaler be approved by the Board as a
condition for the issuance of a wholesaler
permit; the applicant for a wholesaler license would be required to certify that it
meets the requirements of section 1780 at
the time of licensure or renewal. Additionally, the changes would update the references to the United States Pharmacopeia
Standards to reflect the twenty-third revision now in use.
At this writing, the Board is scheduled
to hold a public hearing on these proposed
changes on January 24 in El Segundo.
Graduates of Foreign Pharmacy
Schools. Also on November 17, the Board
published notice of its intent to amend
section 1720.1, Title 16 of the CCR, which
describes the requirements for pharmacist
licensure for foreign pharmacy school graduates, including evaluation of their pharmacy school coursework. Among other
things, the Board's proposed changes would
remove an existing reference to coursework

evaluation by the Credentials Evaluation
Service of the International Education Research Foundation. Also, the educational
eligibility component required for admission to the pharmacist licensure examination would be limited to receipt of a satisfactory grade on the Foreign Pharmacy
Equivalency Examination; a combination
of foreign and domestic coursework would
no longer establish eligibility.
At this writing, the Board is scheduled
to hold a public hearing on these proposed
changes on January 24 in El Segundo.
Rulemaking Update. The following
is a status report on the Board's rulemaking proposals discussed in previous issues
of the Reporter
- MedicalDevice RetailerLocked Storage. On August 1, the Office of Administrative Law (OAL) approved the Board's
amendments to section 1748. i, Title 16 of
the CCR, which expand the personnel authorized to provide emergency or afterhours delivery of dangerous devices to
patients of a medical device retailer to
include an employee who operates a service vehicle. [15:2&3 CRLR 88; 14:1 CRLR
74]
. Examination Admission Requirements. On August 4, OAL approved the
Board's amendments to section 1719, Title
16 of the CCR, which specify that candidates taking the Test of Spoken English
(TSE) after June 30, 1995 must achieve a
score of at least 50, while candidates taking the TSE before June 30, 1995 are
subject to the previous minimum score of
220. [15:2&3 CRLR 88]
- Revisions to Building and Security
Standards. At its July 26 meeting, the
Board held a public hearing on its proposal to repeal sections 1711, 1712, 1713,
and adopt new section 1714, Title 16 of
the CCR. Proposed section 1714 would
streamline the pharmacy licensure application for pharmacies licensed after July
1, 1996, and would apply to all licensed
pharmacies after January 1, 1998. The
proposed section would eliminate the existing floor plan review and approval process and replace it with simplified general
building standards defined with less restrictive physical criteria. [15:2&3 CRLR
891
After the public hearing, the Board
made two modifications to the text of proposed section 1714. The first modification
clarifies that subsection (a) will apply to
all pharmacies; the second modification
requires "new" pharmacies governed under
section 1714 to have a "readily accessible
restroom" which must contain a toilet and
washbasin with running water. The Board
adopted the proposed section 1714 subject
to these modifications; on July 31, the
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Board released the modified version of
proposed section 1714 for a 15-day public
comment period which expired on August
21.
At its October 26 meeting, the Board
proceeded to further modify section 1714;
among other things, the Board made additional textual modifications to clarify its
intent to require all pharmacies (not just
newly-licensed pharmacies) to have a private consultation area. The Board again
adopted section 1714 with these added
modifications and released the revised
text for another 15-day public comment
period in November.
Following the second 15-day public
comment period, the Board submitted the
rulemaking file to the Department of Consumer Affairs (DCA) on November 22;
DCA approved the proposal on December
28. At this writing, the rulemaking file
awaits review and approval by OAL.
- Citationand Fine Program.On May
31, OAL approved the Board's addition of
new Article 9.5, commencing with section
1775, Title 16 of the CCR, establishing a
citation and fine program. The provisions
authorize a Board inspector or committee
to issue citations containing orders of
abatement and/or fines for the unlicensed
practice of pharmacy and for violation of
the pharmacist's duty to provide oral consultation before dispensing medication.
[15:2&3 CRLR 90; 15:1 CRLR 84; 14:4
CRLR 91-92]

U

LEGISLATION

Future Legislation. At its July meeting, the Board agreed to pursue legislation
to place the administration of the triplicate
monitoring program for controlled substances with the Board (see MAJOR PROJECTS).
AB 611 (Aguiar), as amended July 3,
creates a new licensure program to be
administered by the Board-the veterinary food-animal drug retailer, defined as
a place (other than a pharmacy) that holds
a valid wholesaler certificate, license, permit, or registration, from which veterinary
drugs for food-producing animals are dispensed to a prescription from a veterinarian, and which is issued a permit for that
location by the Board. The bill defines the
term "veterinary food-animal drugs" to
include any drug intended for use in foodproducing animals that, by federal or state
law, may be dispensed only by the prescription of a licensed veterinarian.
Under AB 611, a veterinary food-animal drug retailer must be placed under the
charge of a responsible person exempt
from the pharmacist registration requirement, who has completed a training program approved by the Board and passed

an examination administered by the Board;
may dispense veterinary food-animal drugs
for food-producing animals under specified conditions; and may dispense veterinary food-animal drugs only to another veterinary food-animal drug retailer, a pharmacy, a veterinarian, or to a veterinarian's
client pursuant to a veterinarian's prescription.
AB 611 also establishes minimum standards for veterinary food-animal drug retailers, and requires them to establish written policies and procedures regarding certain information. The bill also requires a
consulting pharmacist to be retained to
review these policies and procedures, and
to certify at least twice a year whether the
retailer is in compliance with the requirements of the Pharmacy Law. The bill also
establishes the initial fee for a veterinary
food-animal drug retailer certificate, license, permit, or registration at $400, and
establishes the renewal fee at $250. This
bill was signed by the Governor on August
3 (Chapter 350, Statutes of 1995).
AB 1107 (Campbell). Under existing
law, the right to sell or furnish prescription
lenses is limited exclusively to licensed
physicians, optometrists, and registered
dispensing opticians. As amended August
28, this bill authorizes, notwithstanding
that limitation, a pharmacist to dispense
replacement contact lenses, as defined, in
accordance with certain requirements.
These requirements are also made applicable to nonresident pharmacists.
Existing law requires nonresident
pharmacies, as defined, to register with the
Board and to disclose certain information
to the Board; and provides for the denial,
revocation, and suspension of nonresident
pharmacy registration for failure to comply with certain requirements. This bill
adds the requirements for dispensing replacement contact lenses to the requirements for which nonresident pharmacy
registration may be denied, revoked, or
suspended. The bill requires that nonresident pharmacies comply with certain requirements, maintain certain records, and
disclose certain information to the Board.
This bill also adds the requirement that
those pharmacies maintain records of all
replacement contact lenses shipped,
mailed, or delivered to California residents; and requires that these records be
available for inspection upon request by
the Board or the Division of Licensing of
the Medical Board of California (MBC).
This bill also requires any pharmacy, including nonresident pharmacies, dispensing replacement contact lenses to comply
with certain laws governing advertising of
contact lenses, and to register with MBC
at the time of initial licensure or registra-
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tion or upon renewal of the license or
registration. This bill was signed by the
Governor on October 9 (Chapter 719,
Statutes of 1995).
AB 1529 (Vasconellos). Existing law
generally prohibits the possession of marijuana or concentrated cannabis and prohibits the planting, cultivating, harvesting,
drying, or processing of marijuana. As
amended September 5, this bill would
have provided that these prohibitions do
not apply to any person who possesses,
plants, cultivates, harvests, dries, or processes marijuana for his/her own personal
medicinal use or for the personal medicinal use of another of whom the person is
an immediate family member or for whom
the person is the legal guardian or primary
caretaker, as defined, where the medicinal
use has been approved in writing by a
licensed physician for the treatment of
AIDS, cancer, glaucoma, or multiple sclerosis. This bill was vetoed by the Governor on October 15.
SB 988 (Polanco). Existing law provides for the licensure, regulation, and
discipline of pharmacists and pharmacies
by the Board; existing law exempts certain
activities, drugs and devices, and facilities
from the application of this law. As amended
April 25, this bill also exempts the furnishing of dangerous drugs and devices, as
defined, to recognized schools of nursing,
in certain circumstances. This bill also
authorizes a wholesaler or pharmacy to
furnish dangerous drugs to certain officers
of an ocean vessel in accordance with
certain procedures and federal regulations.
[15:1 CRLR 87]
Existing law also sets forth the requirements for licensure as a pharmacist for
applicants who graduate from a foreign
pharmacy school. This bill revises those
requirements. [15:1 CRLR 86]
SB 988 also revises requirements relating to the filing of petitions for reinstatement of a revoked or suspended certificate, or any other license, registration, permit, or exemption issued by the Board,
and requires the automatic suspension of
a pharmacist's certificate if the pharmacist
or other licensee, certificant, permittee,
registrant, or exemptee is incarcerated
after conviction of a felony in accordance
with specified procedures. This bill was
signed by the Governor on September 2
(Chapter 442, Statutes of 1995).
AB 1136 (V. Brown). Existing law
provides for the licensure and regulation
of health care service plans (HCSP) by the
Department of Corporations. Existing law
defines a specialized HCSP contract as a
contract for health care services in a single
specialized area of health care, including
dental care. As amended September 12,
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this bill would revise this definition to
clarify that the contract may be for pharmaceutical benefits. It would also require,
commencing January 1, 1998, the Commissioner of Corporations to ensure that
when formularies are created for pharmaceutical benefits, the formularies are subject to review by the plan's quality assurance program.
The Pharmacy Law provides for the
licensure and regulation of pharmacists,
to be administered by the Board. Existing law imposes various requirements on
HCSPs and insurers, and permits those
plans and insurers to enter into various
contracts with health care providers. Existing law requires each HCSP to disclose
certain information regarding the benefits,
services, and terms of the plan contract in
order to provide the public, subscribers,
and enrollees with a full and fair disclosure of the terms of the plan. This bill
would require a HCSP to disclose the extent that the plan pays or offers to pay
financial remuneration to a dispenser for
substituting a prescribed drug for another
drug.
Existing law states the intent of the
legislature regarding HCSPs. This bill
would also state the intent relating to the
dispensing of pharmaceutical drug benefits by those plans. [A. Conference Committee]
AB 1113 (Rogan). Existing law categorizes controlled substances into five
schedules; only controlled substances in
Schedules II to V, inclusive, may be prescribed, and only as specified. Existing
law categorizes levoalphacetylmethadol
(LAAM) as a Schedule I controlled substance; as amended July 15, this bill transfers LAAM from Schedule I to Schedule
II, thus allowing it to be prescribed. This
bill was signed by the Governor on September 2 (Chapter 455, Statutes of 1995).
AB 322 (Alpert), as introduced February 9, would transfer the controlled substance methylphenidate from Schedule II
to Schedule III. [A. PubS]
AB 1163 (V. Brown). Existing law
provides for the licensure and regulation
of pharmacists and provides that a violation of the provisions regulating the practice of pharmacy is subject to criminal
sanction. Existing law also provides that a
registered nurse who is authorized by administrative regulations and is employed
by or serves as a consultant for a licensed
skilled nursing, intermediate care or other
health care facility, may orally or electronically transmit to the furnisher a prescription lawfully ordered by a person authorized to prescribe drugs or devices, and
requires the furnisher to record the name
of the person who transmits the order. As
120

introduced February 23, this bill would
similarly permit a registered nurse who is
employed by a home health agency to
orally transmit a prescription, and require
the furnisher to record the name of the
person who transmits the order. [A. Floor]
SB 641 (Craven). Existing law authorizes a licensed pharmacist to dispense
drugs upon a transmittal order of a physician assistant (PA) who has been delegated that authority by a physician. As
introduced February 22, this bill would
state the intent of the Legislature to enact
guidelines for pharmacists who accept
Schedule II prescriptions from PAs in accordance with those provisions. [S. B&P]
SB 922 (Meilo). Existing law requires
the Board to adopt regulations that apply
the same requirements or standards for
oral consultation to certain out-of-state
pharmacies that are applied to certain instate pharmacies, and provides that the
regulations shall not result in any unnecessary delay in patients receiving their
medication. As introduced February 23,
this bill would additionally provide that
the regulations shall also not result in any
unnecessary expense to patients receiving
their medication. [S. B&P]
SB 959 (Mello), as introduced February 23, would state the intent of the
legislature that pharmacists be prohibited
from receiving compensation for the dispensing of prescription drugs beyond a
predetermined dispensing fee established
by the patient's insurance carrier. [S. Rls]
SB 777 (Polanco). Existing law excludes from the practice of psychology the
prescribing of drugs. As amended May 2,
this bill would require the Board of Psychology to establish and administer a certification program to grant licensed psychologists prescriptive authority, as defined, and to develop procedures for that
certification with the advice of the state
Department of Health Services and the
Board of Pharmacy. The bill would require each applicant for certification to
satisfy certain educational and training requirements. This bill would also delete the
exclusion of the prescribing of drugs by
certified psychologists from the practice
of psychology. [S. B&P]
SB 510 (Maddy), as amended May 2,
would authorize optometrists to use specified diagnostic drugs and to prescribe
specified therapeutic pharmaceutical
agents (TPAs) incidental to their practice
of optometry (excluding controlled substances). Currently, California optometrists have no prescriptive authority. This
bill would make it a misdemeanor for any
optometrist to refer a patient to a pharmacy that is owned by the optometrist or
in which the optometrist has a proprietary

interest (see agency report on BOARD OF
OPTOMETRY for a detailed discussion of
this bill). [S. B&P]
AB 1969 (Isenberg), as amended
April 5, is substantially similar to SB 510
above; however, instead of providing that
any use, prescribing, or dispensing of TPAs
to a patient by an optometrist is limited to
that which is incidental to the practice of
optometry, AB 1969 would require that
such use, prescribing, or dispensing of a
pharmaceutical agent be limited only to
the practice of optometry. [A. Health]
AB 1572 (Allen), as amended May 2,
would, among other things, repeal the existing Pharmacy Law and reenact it as
revised as reorganized. The purpose of the
bill is not to change any substantive provision of existing pharmacy law, but to
recast it into a more organized format and
to eliminate duplication and archaic language. This bill is sponsored by the Board
of Pharmacy and is the product of several
years of work by the Pharmacy Law Committee. [A. Health]
*

LITIGATION
In Smith v. CaliforniaState Board of
Pharmacy, 37 Cal. App. 4th 229 (July 31,
1995), the Fourth District Court of Appeal
reversed the San Diego County Superior
Court's judgment denying Thomas Smith's
petition for a writ of administrative mandamus; Smith sought the writ in order to
set aside the decision of the Board, which
adopted the ruling of an administrative
law judge (ALJ) and revoked Smith's license to practice pharmacy. The ALJ's
decision was based in part on a negligence
theory which was not alleged in the accusation filed against Smith. In reversing the
superior court's ruling which denied the
petition for writ of mandate, the Fourth
District held that the failure of the accusation to give Smith adequate notice that the
Board was going to rely upon a theory of
negligence constituted a procedural due
process violation.

U

RECENT MEETINGS
At its May 24 meeting, the Board met
with Senior Assistant Attorney General
Ron Russo to discuss the disciplinary process, particularly the Board's concern about
the length of time required by the Attorney
General's Office to file a case and then
prosecute it before an administrative law
judge (ALJ) from the Office of Administrative Hearings (OAH). Russo explained
that in the past, some cases have been
backlogged for several years due to staffing constraints at the AG's Office and
calendar overload at OAH. However, he
reported that additional deputies have
been hired and statistics show that the
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timeframe for processing cases has improved. The Board and Russo agreed that
in those cases when settlement terms are
requested, Board staff will prepare these
terms in a boilerplate format to be modified as needed by the deputy attorney general assigned to the case.
Also on May 24, member Marilyn
Shreve requested that the Board institute
a reporting system requiring employers of
licensees to report to the Board when they
seek termination of a licensee for drug-related reasons. Employment laws and liabilities have discouraged employers from
reporting the fraudulent activities of their
employees. Several issues concerned the
Board, including whether employers
should also report pharmacists who make
significant or multiple errors, and whether
the employer would be exempt from liability should the Board use reported information to take disciplinary actions against
the pharmacist. The Board's Recovery
Program, which began in 1985, provides
a less threatening mechanism whereby
management can report impaired pharmacists, as pharmacists enter the program by
employer referral or voluntarily for treatment without the Board's knowledge.
However, when theft of drugs is involved
and loss of a controlled substance is not
accounted for as required by law, then the
Board must take appropriate disciplinary
action or impose mandatory program
treatment in lieu of discipline. The Board
resolved to discuss this matter in its next
newsletter.
On May 25, Shreve reported on the
progress of the consumer education plan
directed toward educating the public
about the new pharmacist consulting law.
[15:2&3 CRLR 93; 15:1 CRLR 87; 14:4
CRLR 94] Board staff has incorporated the
new logo adopted by the Board with the
slogan "Be Aware and Take Care: Talk to
Your Pharmacist" on the Board's printed
materials. At its July meeting, the Board
resumed discussion of this matter, noting
that National Pharmacy Week had been
scheduled for October 22-28, with the
theme of "Communicate Before You Medicate." Various other Board efforts to promote consumer education are also under
way, including development of a media
package with educational videotapes, and
press conferences to be held in conjunction with schools of pharmacy and professional associations in California's major
cities.
Also on May 25, the Board elected
Marilyn Standifer Shreve as its new president, Darlene Fujimoto as vice-president,
and Caleb Zia as treasurer.
At its July 26 meeting, the Board resumed discussion of its concern that OAH

ALJs have not consistently adhered to the
Board's disciplinary guidelines in enforcement proceedings, especially in serious drug diversion cases. Senior Assistant
Attorney General Ron Russo reported that
OAH is drafting "Rules of Court" which
will formalize procedures for more consistency in adjudication. The Board also considered various options to improve the
efficiency of processing disciplinary matters, including seeking limited peace officer status for some Board inspectors and
incorporating new methods of undercover
operations and surveillance. The Board
further requested Deputy Attorney General Bill Marcus to draft amendments to
Business and Professions Code section
4232 to modify the current treatment of
unaccounted-for controlled substances in
drug diversion cases. Under existing law,
this is only considered a recordkeeping
violation; the Board would like the legislature to amend section 4232 to enable it to
treat such violations as justification for
charges of diversion with the penalty of
license revocation.
At its July 26 meeting, the Board discussed the procedure for setting appropriate levels of supervision for licensees on
probation. The Northern Interim Committee (NIC) and the Southern Interim Committee (SIC), each consisting of three
Board members and Board inspectors,
were created to oversee this process. The
NIC and SIC hold meetings at which a
pharmacist on probation submits a letter
from his/her employer verifying the current level of supervision. The NIC or SIC
reviews the information and the circumstances of the case and then requires a
specified level of supervision during the
probation period. There are four general
levels of supervision: continuous (75% to
100% of a shift), substantial (at least 50%
of a shift), partial (at least 25% of a shift),
and daily review (supervisor's review of
probationer's daily activities within a 24hour period). A probationer may appeal a
required level of supervision and request
modification. To avoid excessive restraints
on the licensee's practice that would prevent gainful employment during the probation period, the Board may reduce the
supervision level and increase the frequency of monitoring by an inspector. The
Board delegated to the supervising inspectors the authority to set the level of supervision for the probationer at an earlier
stage. The level would be set at a probation
office conference with the licensee; no
appeal process would follow (the supervision level for all probationers is reviewed
annually, however, by the supervising inspector); the supervision level must be
written clearly, signed by the probationer,
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and kept on file. In delegating this authority, the Board intends to provide its supervising inspectors with specific guidelines
for establishing an appropriate level of
supervision. At its October 26 meeting,
the Board adopted a set of proposed guidelines for setting supervision level for probationers. While in general cases the guidelines do not provide for an appeal once a
supervision level is set, appeals will be
considered by the Executive Officer and
supervising inspector after 90 days in extreme circumstances where the probationer
can document a hardship. DCA legal counsel Chris Grossgart clarified that the guidelines are not binding regulations on inspectors, but serve as a guide for them to
use in their discretion. The Board further
explained that the guidelines are intended
for use in those cases where only general
supervision exists and no specific conditions of probation have been set by the
Board.
Also at its October meeting, the Board
discussed FDA's proposed adoption of 21
C.F.R. Parts 201,208,314, and601, which
would establish the requirements for prescription drug product labeling and written medication guides. FDA has determined that statistics show patient compliance with the proper use of a drug is best
achieved when a patient receives both oral
consultation and useful written information when the prescription is dispensed.
FDA's "Healthy People 2000" goal proposes that by 2000,75% of Americans will
receive written information with each new
prescription, increasing to 95% by 2006.
FDA is considering the "Med Guide"
program, much like the successful food
labeling programs, which is aimed at providing useful written drug information in
a consistent format. The Board noted that
while many Californians currently receive
written information about their prescriptions on the drug dispensing receipt, the
printed format and content of drug information vary from pharmacy to pharmacy.
The Board acknowledged that it would be
difficult to provide written information for
diverse medication situations. However,
the Board suggested that this could be
addressed when FDA implements a standard format for printed drug information
by providing a computerized format with
a comment area for pharmacists to customize the information to address the
patient's entire drug therapy. The Board
noted that because patients do not always
read written information, it is imperative
that the pharmacist discusses and explains
the written information. While improved
drug labeling and a standard format of
drug information is essential, the Board
agreed that the role of a pharmacist to
11
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provide oral consultation to ensure patient
compliance in the proper use of drugs is
equally indispensable.
*
FUTURE MEETINGS
January 24-25 in Los Angeles.
March 27-28 in Sacramento.
May 29-30 in San Diego.
July 24-25 in San Francisco.
October 23-24 in Sacramento.
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he Board of Registration for Professional Engineers and Land Surveyors
(PELS) regulates the practice of engineering and land surveying through its administration of the Professional Engineers
Act, sections 6700 through 6799 of the
Business and Professions Code, and the
Professional Land Surveyors Act, sections
8700 through 8806 of the Business and
Professions Code. The Board's regulations are found in Division 5, Title 16 of
the California Code of Regulations (CCR),
sections 400 through 471.
The basic functions of the Board are to
conduct examinations, issue certificates,
registrations, and/or licenses, and appropriately channel complaints against registrants/licensees. The Board is additionally
empowered to suspend or revoke registrations/licenses. The Board considers the
proposed decisions of administrative law
judges who hear appeals of applicants who
are denied a registration/license, and those
who have had their registration/license
suspended or revoked for violations.
Professional engineers are registered
through the three Practice Act categories
of civil, electrical, and mechanical engineering under section 6730 of the Business and Professions Code. Land surveyors, another Practice Act category, are registered through section 8725 of the Business and Professions Code. The Title Act
categories of agricultural, chemical, control system, corrosion, fire protection, industrial, manufacturing, metallurgical, nuclear, petroleum, quality, safety, and traffic
engineering are registered under section
6732 of the Business and Professions Code.
Structural engineering and geotechnical engineering are "title authorities" linked
to the civil Practice Act and require an
22

additional examination after qualification
as a civil engineer.
The Board consists of thirteen members: seven public members, one licensed
land surveyor, four registered Practice Act
engineers and one Title Act engineer. The
Governor appoints eleven of the members
for four-year terms that expire on a staggered basis. Additionally, both the Assembly Speaker and the Senate Rules Committee appoint one public member each.
The Board has established four standing committees and appoints other special
committees as needed. The four standing
committees are Administration, Enforcement, Examination/Qualifications, and
Legislation. Committees function in an
advisory capacity unless specifically authorized by the Board to make binding
decisions.
PELS is subject to a "sunset" provision. Section 8710 Business and Professions Code, which vests power in the Board,
will "become inoperative on July 1, 1998,
and, as of January 1, 1999, is repealed,
unless a later enacted statute, which becomes effective on or before January 1,
1999 deletes or extends the dates on which
it becomes inoperative and is repealed."
At its July 14 meeting, PELS welcomed
new public member Millicent Safran. In November, public member Megan Matthews
resigned from the Board.

U

MAJOR PROJECTS
Executive Officer Resigns. At a special December 15 PELS meeting, Executive Officer (EO) Harold Turner tendered
his resignation; Turner, who served as the
Board's EO for three years, has taken a
position with the Bureau of State Audits.
Following a closed session, the Board announced the appointment of Cindi Christenson as Interim EO; Christenson is a registered mechanical engineer who has worked
at PELS since 1989. PELS also established a Special Committee for the Recruitment of an Executive Officer, comprised of the Board president, vice-president, and chair of the Administrative Committee, appointed the Board president to
serve as the Committee chair, and authorized the Committee chair to undertake any
actions on behalf of the Board which are
necessary to recruit highly qualified candidates for the EO position, and to report
to the Board at each meeting on the processes that have been implemented and
the progress of the recruitment process.
PELS also decided that the Board itself
should interview highly qualified candidates and make the final hiring decision
by vote, as required by statute.
Professional Engineers Act Rewrite
Goes to Public Forum. PELS is currently

in the midst of a comprehensive review
and rewrite of the Professional Engineers
(PE) Act, its regulations, and the way the
state of California licenses and classifies
various engineering disciplines; this effort
has resulted largely from November 1993
criticism by the Center for Public Interest
Law (CPIL) that PELS' engineering statutes and regulations are extremely vague
and in need of major restructuring and
modernization, and former Board President Rich Johnson's "white paper" entitled Confronting the Issues ofEngineering
Discipline Definitions, in which Johnson
agreed with CPIL that the Board's statutes
are internally inconsistent and lack clarity.
[14:4 CRLR 95; 14:2&3 CRLR 99; 14:1
CRLR 771
Significantly, the Board wants to implement "generic registration," under which
it would grant only one generic PE license
instead of the three Practice Act registrations, thirteen Title Act registrations, and
two "title authority" registrations currently
offered. Generic registration would conform California's licensing system with
those in most other states. The Board feels
the current system's complexity serves no
purpose and only confuses the consumer.
The highlights of PELS' draft PE rewrite
are as follows:
- All registrants would be registered
generically as PEs, with designations as to
areas of practice in which they have been
"deemed qualified" by testing, rather than
being registered in specific branches of
engineering. All registrants would be required to provide engineering services in
a competent manner, and their registration
would be at risk if they fail to do so.
- Traditional Title Act categories would
be eliminated and essentially converted to
practice acts because generic PE registration would be required in order to perform
prior Title Act work. In other words, all
engineering practice would be regulated
by the Board.
- The rewrite of the PE Act would
allow applicants to test in any of seventeen
areas in which the National Council of
Examiners for Engineering and Surveying
(NCEES) offers an exam. It would eliminate PELS' current registrations in quality,
safety, traffic, and corrosion engineering,
because NCEES does not offer exams in
these disciplines; and add aeronautical,
ceramic, environmental, mining/materials, and structural engineering exams (as
NCEES has developed exams in those
areas). When an applicant passes any
exam, he/she would receive a professional
engineering license and would be "deemed
qualified" in the area tested, but could
practice in any area of engineering. For
example, a PE who has tested in agricul-
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